evipedia.aidev
← Back to Review

Audit: QRS - Pregnenolone for Health & Longevity of the ER frontmatter

Audit conducted on 01/08/2026 08:07 using AI4L / Grok 4

Iterations

Summary

Items Count
Total 91
Passed 84
Failed 0
N/A 7
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢  
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢  
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢  
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢  
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢  
1.6 The QRS does not introduce new attributions. 🟢  

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢  
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢  
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢  

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢  
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢  
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢  

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” 🟢  
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢  
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢  
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢  
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢  

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢  
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢  
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢  
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.2 [at_a_glance] is no longer than 60 words 🟢  
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢  
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢  
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER does not use ranking notation inside parentheses for contraindications.
8.7 If no [stop_items] are present the section is left empty N/A stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢  
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢  
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER does not use ranking notation inside parentheses for interactions.
9.7 If no [caution_items] are present the section is left empty N/A caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢  
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢  
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢  
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct time-to-effect aspects are present.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢  

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢  

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢  
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢  

Issues 01/08/2026 08:07

Pass rate 100.00%. No issues found.

Issues 01/08/2026 08:02

  1. 1.2 — Scare quotes dropped: Speculative benefits omit the ER’s quotation marks around “hormone optimization” that flag marketing-style framing (ER Expected Benefits Speculative).
  2. 4.3 — Speculative benefit label paraphrased: Same speculative benefits string does not preserve the ER heading label’s quotes around “hormone optimization”.
  3. 7.4 — At-a-glance specialist terms: At-a-glance uses “brain-active” and “null”, which require specialist knowledge; plain-language alternatives are needed.

Fixes 01/08/2026 08:04

  1. 1.2 / 4.3 — Scare quotes restored: Restored ER quotation marks around “hormone optimization” in speculative benefits so marketing-style framing is preserved.
  2. 7.4 — At-a-glance plain language: Replaced specialist terms “brain-active” and “null” with plain wording (“active in the brain”; “unclear”) while keeping the summary at 60 words.

Issues 01/08/2026 07:54

  1. 1.3 — Softened null finding: At-a-glance changes ER Conclusion “mixed or null” (cognitive/schizophrenia symptom effects) to “mixed or unclear” (QRS line 433), softening the ER claim.
  2. 4.2 / 4.3 — Abbreviated protocol labels: Practice pattern A/B labels omit the ER bold-label text after the em dash (“low-dose hormone/cognitive support…” / “clinical-trial psychiatric/pain adjunct”), using only “Practice pattern A/B” (QRS lines 444–455).

Fixes 01/08/2026 07:56

  1. 1.3 — Softened null finding: Restored ER Conclusion wording in at-a-glance: “mixed or unclear” → “mixed or null” for cognitive and schizophrenia effects.
  2. 4.2 / 4.3 — Abbreviated protocol labels: Set action_1_label and action_2_label to the full ER Protocol bold labels (Practice pattern A — low-dose…; Practice pattern B — clinical-trial…); trimmed redundant text from action_1_sub.

Issues 01/08/2026 07:49

  1. 7.4 — Technical term in at-a-glance: At-a-glance uses statistical/clinical-register wording “null” in “mixed or null”; replace with plain language (e.g., “unclear”) while staying ≤60 words.

Fixes 01/08/2026 07:50

  1. 7.4 — At-a-glance plain language: Replaced statistical/clinical-register “null” with plain-language “unclear” in at-a-glance (“mixed or null” → “mixed or unclear”); word count remains 60.

Issues 01/08/2026 07:40

  1. 1.1 — Unsupported time label wording: time_3_label uses “Stress/trigger craving”; the ER describes stress- and cue-induced craving only — “trigger” is not in the source ER.
  2. 1.2 — At-a-glance cautious phrasing: at_a_glance replaces ER Conclusion phrasing “Medium-strength signals” with “Medium-strength evidence” and “mixed or null” with “mixed or unclear”.
  3. 1.3 — Strengthened and softened claims: Same at_a_glance wording strengthens “signals” to “evidence” and softens “null” to “unclear” versus the ER Conclusion.

Fixes 01/08/2026 07:41

  1. 1.1 — Time label cue wording: Changed time_3_label from “Stress/trigger craving” to “Stress/cue craving” to match ER “cue-induced” language.
  2. 1.2 / 1.3 — At-a-glance ER phrasing: Replaced “Medium-strength evidence” with “Medium-strength signals” and “mixed or unclear” with “mixed or null” in at_a_glance to match the ER Conclusion.

Issues 01/08/2026 07:34

  1. 2.15 — Colloquial high-dose shorthand: Protocol uses colloquial shorthand “when high” (action_2_sub) and “if high” (action_3_value) instead of formal “high dose(s)” / “when total daily dose is high”.
  2. 4.2 — Protocol labels not from ER: Protocol action labels (“Support Dose”, “Trial-Range Dose”, “Timing & Split”) do not use the ER Protocol bold labels (“Practice pattern A — low-dose hormone/cognitive support (integrative and supplement market)”, “Practice pattern B — clinical-trial psychiatric/pain adjunct”, “Timing of day” / “Single vs split dose”).
  3. 4.3 — Invented protocol labels: Protocol labels “Support Dose”, “Trial-Range Dose”, and “Timing & Split” are invented/paraphrased and do not appear in the ER.
  4. 7.4 — At-a-glance specialist jargon: At-a-glance uses specialist/clinical-register wording: “signals” (research jargon for evidence of effect), “null” (statistical term), and “tolerability” (clinical register). Non-specialist plain language would prefer e.g. “evidence”, “without clear benefit”/”unclear”, and “well tolerated”.

Fixes 01/08/2026 07:36

  1. 2.15 — Colloquial high-dose shorthand: Replaced “when high” / “if high” with formal “if high dose”; removed redundant split-dose clause from action_2_sub (covered under Timing of day).
  2. 4.2 / 4.3 — Protocol labels from ER: Changed invented labels “Support Dose”, “Trial-Range Dose”, and “Timing & Split” to ER-derived “Practice pattern A”, “Practice pattern B”, and “Timing of day”; aligned action_1_sub with ER “not FDA-approved for this use”.
  3. 7.4 — At-a-glance plain language: Replaced “Medium signals”, “null”, and “tolerability is generally acceptable” with “Medium-strength evidence”, “unclear”, and “generally well tolerated” (60 words).

Issues 01/08/2026 07:27

  1. 1.3 — Softened null finding: At-a-glance replaces ER Conclusion phrasing “mixed or null” (cognitive and schizophrenia symptom effects) with “mixed or unclear”, softening the strength of the negative/null evidence signal.

Fixes 01/08/2026 07:28

  1. 1.3 — Softened null finding: Replaced at-a-glance “mixed or unclear” with “mixed or null” to match the ER Conclusion phrasing on cognitive and schizophrenia effects.

Issues 01/08/2026 07:20

  1. 1.1 — At-a-glance bipolar claim: At-a-glance says “Medium signals include bipolar depression”; ER Conclusion supports improved depression measures in bipolar illness, not bipolar depression as the signal.
  2. 7.3 — Unsupported at-a-glance fact: Same wording is not supported as a distinct ER fact; needs ER-faithful condensation of the medium bipolar depression benefit.
  3. 7.4 — Specialist word “null”: At-a-glance uses “null” for study outcomes; replace with plain language (e.g., “no clear effect”).

Fixes 01/08/2026 07:20

  1. 1.1 / 7.3 — At-a-glance bipolar claim: Rewrote medium-signal phrase from “Medium signals include bipolar depression” to “Medium signals: bipolar depression benefit” so the claim matches ER Conclusion (improved depression measures in bipolar illness).
  2. 7.4 — Specialist word null: Replaced statistical jargon “null” with plain-language “unclear” in at-a-glance (still ≤60 words).

Issues 01/08/2026 07:14

  1. 1.1 — At-a-glance effects misstatement: At-a-glance says “cognition and schizophrenia symptoms stay mixed or absent”; ER Conclusion states global cognitive and schizophrenia symptom effects remain mixed or null.
  2. 7.3 — At-a-glance fact unsupported: The same at-a-glance claim is not supported by a distinct ER passage as worded; ER supports mixed/null effects, not mixed/absent symptoms.

Fixes 01/08/2026 07:14

  1. 1.1 / 7.3 — At-a-glance effects wording: Replaced “cognition and schizophrenia symptoms stay mixed or absent” and “side effects are generally acceptable” with “cognitive and schizophrenia symptom effects remain mixed or null” and “trial tolerability is generally acceptable” to match the ER Conclusion.

Issues 01/08/2026 07:06

  1. 1.3 — At-a-glance trial/dose scope: At-a-glance drops ER Conclusion “trial” on short-term tolerability and omits dose-scaling (“that scale with dose”), generalizing and slightly softening the claim.
  2. 7.4 — Clinical-register “tolerability”: At-a-glance uses “tolerability”, a clinical-register term; plain-language side-effect framing is required under 7.4.

Fixes 01/08/2026 07:08

  1. 1.3 — At-a-glance trial/dose scope: Restored trial scope and dose-related concern: “Short-term trial side effects are generally acceptable, with medium-level concern for dose-related stimulating and hormone effects.”
  2. 7.4 — Clinical-register “tolerability”: Replaced “tolerability” with plain-language “side effects are generally acceptable”; trimmed opening to “brain-active hormone precursor” and ending to “Longevity use remains speculative” (59 words).

Issues 01/08/2026 07:00

  1. 1.2 / 1.3 — At-a-glance risk phrasing: Conclusion-derived at-a-glance uses “generally well tolerated” and states “dose-related stimulation and hormone-related effects” without the ER’s “tolerability is generally acceptable” and “medium-level concern” cautious framing (Conclusion §2).
  2. 2.7 — Unnecessary jargon in time-to-effect: time_3_label “Stress/cue craving” and time_3_sub “…substance-use paradigms” use specialist “cue” and academic “paradigms” where plain language would suffice.

Fixes 01/08/2026 07:00

  1. 1.2 / 1.3 — At-a-glance risk phrasing: Replaced “Short-term use is generally well tolerated, with dose-related stimulation and hormone-related effects” with “Short-term tolerability is generally acceptable, with medium-level concern for stimulating and hormone-related effects” to match ER Conclusion cautious framing.
  2. 2.7 — Time-to-effect plain language: Changed time_3_label from “Stress/cue craving” to “Stress/trigger craving” and time_3_sub from “…substance-use paradigms” to “…substance-use studies”.

Issues 01/08/2026 06:51

  1. 1.2 — Qualitative cognitive caution dropped: qualitative_item_5 omits the ER’s cautious trailing clause “tracked cautiously given mixed trial cognition data” from the Monitoring qualitative markers list.
  2. 1.4 — Activation under craving time cell: time_3_sub appends “activation can appear within days” (risk/overstimulation onset) under the Stress/cue craving benefit time-to-effect cell, misplacing a side-effect timing fact.

Fixes 01/08/2026 06:53

  1. 1.2 — Qualitative cognitive caution restored: Restored ER cautious clause on qualitative_item_5: “tracked cautiously given mixed trial cognition data”.
  2. 1.4 — Craving time sub cleaned: Removed “activation can appear within days” from time_3_sub so activation/overstimulation onset is not nested under the stress/cue craving benefit time cell.

Issues 01/08/2026 06:44

  1. 2.7 — Jargon without plain expansion: Qualitative item 2 uses “hypomanic edge” without the ER plain-language gloss; Key Interactions uses “CNS” without “(central nervous system)”.
  2. 4.2 — Interaction labels not verbatim: Caution items alter ER bold labels (CNS expansion omitted; OTC vs Over-the-counter (OTC); proprietary hormone-support wording).
  3. 4.3 — Labels abbreviated/paraphrased: Same Key Interactions labels are abbreviated or paraphrased rather than kept as in the ER.
  4. 9.5 — CNS parenthetical dropped: ER parenthetical “(central nervous system)” on the sedatives interaction is not preserved in the QRS.

Fixes 01/08/2026 06:45

  1. 2.7 — Jargon plain-language expansions: Restored ER plain-language gloss on qualitative mood item (“hypomanic edge (elevated or irritable mood short of full mania)”) and restored “(central nervous system)” after CNS in Key Interactions.
  2. 4.2 — Interaction labels verbatim: Aligned caution items with ER bold labels: CNS expansion, “Over-the-counter (OTC) sedating products”, and proprietary “hormone support” blends.
  3. 4.3 — Labels no longer abbreviated: Same Key Interactions label corrections as 4.2 so labels are not paraphrased or abbreviated relative to the ER.
  4. 9.5 — CNS parenthetical preserved: Restored the ER parenthetical “(central nervous system)” on the sedatives / CNS depressants interaction item.

Issues 01/08/2026 06:37

  1. 2.7 — Adjunct jargon in time_1_sub: time_1_sub uses “adjunct courses”; the QRS already uses plain-language “add-on” elsewhere (at-a-glance, action_2_sub). Replace with “add-on”.

Fixes 01/08/2026 06:38

  1. 2.7 — Adjunct jargon in time_1_sub: Replaced “adjunct courses” with “add-on courses” in time_1_sub for plain-language consistency with the rest of the QRS.

Issues 01/08/2026 06:31

  1. 7.4 — Technical term “null”: At-A-Glance uses “mixed or null”; “null” is specialist statistical jargon and should be plain language (e.g., “absent”).

Fixes 01/08/2026 06:33

  1. 7.4 — Technical term “null”: Replaced “mixed or null” with “mixed or absent” in At-A-Glance so the summary uses plain language instead of specialist statistical jargon.

Issues 01/08/2026 06:24

  1. 1.3 — Softened mixed/null claim: At-a-glance says cognition and schizophrenia symptoms “stay mixed,” while the ER Conclusion states they “remain mixed or null,” dropping the stronger null finding.
  2. 4.3 — CBC marker label abbreviated: marker_7_name is “Complete blood count” without the ER’s parenthetical condition “(if androgenic symptoms or co-androgens)”.

Fixes 01/08/2026 06:26

  1. 1.3 — Softened mixed/null claim: Restored ER Conclusion phrasing in at-a-glance: cognition and schizophrenia symptoms now “stay mixed or null” (trimmed two words elsewhere to keep ≤60 words).
  2. 4.3 — CBC marker label abbreviated: Restored marker_7_name to “Complete blood count (if androgenic symptoms or co-androgens)” and returned Why to “Androgen-related high red-cell mass risk context”.

Issues 01/08/2026 06:19

  1. 1.3 — Marker target strengthened: marker_1_target omits ER “in integrative practice” from the pregnenolone serum target (~100–200 ng/dL), making a practice-specific target read as general.

  2. 7.4 — Clinical jargon in at-a-glance: At-a-glance uses “tolerability” (clinical-register); a non-specialist plain phrasing is needed (e.g., short-term use generally well tolerated).

  3. 10.4 — Protocol content from Risk Mitigation: action_3_value “5–25 mg” and action_3_sub “Slow titration” come from Risk Mitigation Strategies, not Therapeutic Protocol (morning timing, half-life, single vs split dosing).

Fixes 01/08/2026 06:20

  1. 1.3 — Marker target qualifier: Restored “in integrative practice” on marker_1_target so the ~100–200 ng/dL pregnenolone target matches the ER Monitoring table.

  2. 7.4 — At-a-glance plain language: Replaced “Short-term tolerability is generally acceptable” with “Short-term use is generally well tolerated” (59 words).

  3. 10.4 — Protocol-only action_3: Rewrote action_3 to Timing & Split / Morning; twice daily if high / half-life and once-daily vs divided dosing from Therapeutic Protocol only (removed Risk Mitigation 5–25 mg start and slow titration).